BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

De­spite strong third-quar­ter rev­enues, BioN­Tech has soft­ened its 2024 sales guid­ance in light of changes to Covid-19 vac­cine up­take, pric­ing and sea­son­al vari­a­tions.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.